103196-77-6

Upstream product

• 67-56-1 methanol 
• 169217-35-0 (2R,3R,3'R)-3-hydroxy-2-(3'-hydroxy-15'-methylhexadecanoylamino)-15-methyl-hexadecan-1-sulfonic acid 
• 326794-45-0 C₃₄H₆₉NO₄ 

Relevant academic research and scientific papers

Sulfobacins A and B, novel von Willebrand factor receptor antagonists. II. Structural elucidation

Sulfobacins A and B are novel von Willebrand factor (vWF) receptor antagonists produced by Chryseobacterium sp. NR 2993. The structures of sulfobacins A and B have been determined to be (2R,3R)-3-hydroxy-2-[(R)-3-hydroxy-15-methylhexadecanamido]-15- methylhexadecanesulfonic acid and (2R,3R)-3-hydroxy-15-methyl-2-[13-methyltetradecanamido]- hexadecanesulfonic acid, respectively, by various 2D NMR experiments and by methanolysis. The absolute configurations of the sulfobacins were determined by a modified MOSHER's method. The structures are related to sulfonolipids, major components of the cell envelope of gliding bacteria of the genus Cytophaga.

GLYCOSPHINGOLIPIDS FOR USE IN MODULATING IMMUNE RESPONSES

Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.